Yeo C J, Cameron J L, Sohn T A, Coleman J, Sauter P K, Hruban R H, Pitt H A, Lillemoe K D
Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Ann Surg. 1999 May;229(5):613-22; discussion 622-4. doi: 10.1097/00000658-199905000-00003.
This prospective, randomized, single-institution trial was designed to evaluate the end points of mortality, morbidity, and survival in patients undergoing standard versus radical (extended) pancreaticoduodenectomy (including distal gastrectomy and retroperitoneal lymphadenectomy).
Numerous retrospective reports and one prospective randomized trial have suggested that the performance of an extended lymphadenectomy in association with a pancreaticoduodenal resection may improve long-term survival for some patients with pancreatic and other periampullary adenocarcinomas. Many of these previously published studies can be criticized for their retrospective and nonrandomized designs, for the inclusion of nonconcurrent control groups, and for their small numbers.
Between April 1996 and December 1997, 114 patients with periampullary adenocarcinoma were enrolled in an ongoing, prospective, randomized trial at The Johns Hopkins Hospital. After intraoperative verification of completely resected periampullary adenocarcinoma, the patients were randomized to receive either a standard pancreaticoduodenectomy (removing only the peripancreatic lymph nodes en bloc with the specimen) or a radical pancreaticoduodenectomy (standard resection plus distal gastrectomy and retroperitoneal lymphadenectomy). All pathology specimens were reviewed and categorized. The postoperative morbidity, mortality, and short-term outcomes were examined.
Of the 114 patients randomized, 56 underwent a standard pancreaticoduodenectomy and 58 a radical pancreaticoduodenectomy. The two groups were statistically similar with regard to age and gender, but there was a higher percentage of white patients in the radical group. All the patients in the radical group underwent distal gastric resection, whereas 86% of the patients in the standard group underwent pylorus preservation. The mean operative time in the radical group was 6.8 hours, compared with 6.2 hours in the standard group. There were no significant differences between the two groups with respect to the intraoperative blood loss, transfusion requirements, location of primary tumor, mean tumor size, positive lymph node status, or positive margin status. There were three deaths in the standard group and two in the radical group. The complication rates were 34% for the standard group and 40% for the radical group. Patients undergoing radical resection had a higher incidence of early delayed gastric emptying but had similar rates of other complications, such as pancreatic fistula, wound infection, intraabdominal abscess, and need for reoperation. The mean total number of lymph nodes resected was higher in the radical group. Of the 58 patients in the radical group, only 10% had metastatic carcinoma in the resected retroperitoneal lymph nodes, and none of those patients had the retroperitoneal nodes as the only site of lymph node involvement. The 1-year actuarial survival rate for patients surviving the immediate postoperative periods was 77% for the standard resection group and 83% for the radical resection group.
These data demonstrate that radical pancreaticoduodenectomy (with the addition of a distal gastrectomy and extended retroperitoneal lymphadenectomy to a standard pancreaticoduodenectomy) can be performed with similar morbidity and mortality to standard pancreaticoduodenectomy. However, the survival data are not sufficiently mature and the numbers of patients enrolled are not adequate to allow firm conclusions to be drawn regarding survival benefit.
本前瞻性、随机、单机构试验旨在评估接受标准与根治性(扩大)胰十二指肠切除术(包括远端胃切除术和腹膜后淋巴结清扫术)患者的死亡率、发病率和生存率等终点指标。
众多回顾性报告和一项前瞻性随机试验表明,胰十二指肠切除术联合扩大淋巴结清扫术可能会提高部分胰腺癌和其他壶腹周围腺癌患者的长期生存率。这些先前发表的许多研究因其回顾性和非随机设计、纳入非同期对照组以及样本量小而受到批评。
1996年4月至1997年12月,114例壶腹周围腺癌患者在约翰霍普金斯医院参与了一项正在进行的前瞻性随机试验。术中证实壶腹周围腺癌完全切除后,患者被随机分为接受标准胰十二指肠切除术(仅将胰腺周围淋巴结与标本整块切除)或根治性胰十二指肠切除术(标准切除术加远端胃切除术和腹膜后淋巴结清扫术)。所有病理标本均进行复查和分类。检查术后发病率、死亡率和短期结局。
114例随机分组的患者中,56例行标准胰十二指肠切除术,58例行根治性胰十二指肠切除术。两组在年龄和性别方面在统计学上相似,但根治组白人患者比例较高。根治组所有患者均接受了远端胃切除术,而标准组86%的患者保留了幽门。根治组平均手术时间为6.8小时,标准组为6.2小时。两组在术中失血、输血需求、原发肿瘤位置、平均肿瘤大小、阳性淋巴结状态或切缘阳性状态方面无显著差异。标准组有3例死亡,根治组有2例死亡。标准组并发症发生率为34%,根治组为40%。接受根治性切除术的患者早期胃排空延迟发生率较高,但其他并发症发生率相似,如胰瘘、伤口感染、腹腔内脓肿和再次手术需求。根治组切除的淋巴结总数平均较高。在根治组的58例患者中,仅10%在切除的腹膜后淋巴结中有转移癌,且这些患者中无一例以腹膜后淋巴结为唯一淋巴结受累部位。术后即刻存活患者的1年预期生存率,标准切除组为77%,根治切除组为83%。
这些数据表明,根治性胰十二指肠切除术(在标准胰十二指肠切除术基础上加远端胃切除术和扩大的腹膜后淋巴结清扫术)的发病率和死亡率与标准胰十二指肠切除术相似。然而,生存数据不够成熟,入组患者数量不足以就生存获益得出确凿结论。